Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease. Show more

Location: 80 Guest St Fl 5, Massachusetts, 02135-2071, US | Website: www.proteostasis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

1.018B

52 Wk Range

$N/A - $N/A

Previous Close

$N/A

Open

$N/A

Volume

N/A

Day Range

$N/A - $N/A

Enterprise Value

0.00

Cash

159.3M

Avg Qtr Burn

N/A

Insider Ownership

19.62%

Institutional Own.

22.57%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date